Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03625648
Other study ID # 2008
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 18, 2019
Est. completion date July 8, 2030

Study information

Verified date April 2024
Source VA Office of Research and Development
Contact Douglas E Lammie, MPH RD
Phone (708) 202-8387
Email douglas.lammie@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.


Description:

Diabetic kidney disease (DKD) is the most frequent cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the U.S. and in U.S. Veterans. Control of blood pressure and reduction in proteinuria, for instance by blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptors blockers (ARBs), have led to some improvement in outcomes in recent years. However, many patients continue to progress to ESRD, requiring costly dialysis or transplantation and resulting in high mortality. Patients with ESRD on maintenance dialysis also have markedly impaired quality of life. Thus, novel treatments are needed for this disease. The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease. Therefore, this drug has been in clinical use for over 3 decades and has been found to have an excellent safety profile. Recent experimental and clinical data suggest that PTX, when added to usual care in patients with DKD, leads to a reduction in albuminuria and reduced inflammation, as evidenced by lower levels of inflammatory cytokines, and may decrease progression of renal disease. The available evidence thus suggests the possibility of the use of PTX as a valuable repurposing of an old drug in the treatment of DKD. However, a large scale multicenter randomized clinical trial is needed to determine whether this agent can reduce hard endpoints such as ESRD and death in patients with DKD. The objective of this study is to test the hypothesis that PTX, when added to usual care, leads to a reduction in the incidence of ESRD and mortality in type-2 diabetic patients with DKD when compared to usual care plus placebo. The primary endpoint will be time to ESRD or death. ESRD will be defined as need for chronic dialysis or renal transplantation. Secondary efficacy endpoints will be: (1) quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF), (2) time until doubling of serum creatinine, (3) hospitalization for congestive heart failure (CHF), (4) a three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), (5) peripheral vascular disease (PVD), (6) percentage of participants with 50% reduction in UACR from baseline, (7) Rate of change in eGFR per year during the study period. Safety (serious adverse events and adverse events possibly or probably related to study drug, discontinuation of study drug) will also be analyzed as a secondary safety outcome. The design will be simple with only 2 face-to-face visits (randomization and end of trial visits). The remaining quarterly contacts can be conducted by telephone collecting minimal targeted information. Laboratory testing specifically for the study will be done only at randomization, at 6 months and the end of the study, if needed. However, coordinators will assure that a serum creatinine will have been measured every 6 months as part of routine clinical care or, in rare instances where one has not been done, obtain this measurement. Other than randomization to PTX or matched placebo, patient care will be handled by usual providers according to recommended standards of care. There will be a one-year ramp-up phase which will include 6 VA hospitals. The purpose of the ramp-up phase will be to optimize procedures prior to widespread implementation, including assessing the recruitment rate to determine whether the expected rate can be achieved and assessing the efficacy of central distribution of study drug/placebo. In addition, the investigators will refine methods of recruitment, demonstrate that the proposed follow-up methods are working as intended, and address unforeseen problems. This will be followed by the full study at 40 sites (which includes the 6 ramp-up sites) and will involve 3 years of recruitment and 5 years of follow-up. Sample size calculation, assuming a 26.6% event rate in the control group and 21.6% event rate in PTX group (corresponding to a 19% relative reduction), two-sided alpha = 0.05, 85% power, a 3-year enrollment period, a minimum 5-year follow-up period, and one proposed interim analysis indicates that 2510 participants will need to be randomized. If this study is successful and PTX is found to reduce the incidence of ESRD and/or death, this will reduce the personal and financial burden of renal replacement therapy (dialysis/transplantation) for Veterans with diabetic kidney disease


Recruitment information / eligibility

Status Recruiting
Enrollment 2510
Est. completion date July 8, 2030
Est. primary completion date January 3, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: A. Inclusion Criteria: 1. Type 2 diabetes. 2. Meet one of the following categories at a time that is greater than 90 days prior to randomization - Group I: eGFR 15 to less than 30 mL/min/1.73 m2, or - Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR > 30 mg/g or UPCR > 150 mg/g, or - Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR > 300 mg/g or UPCR > 500 mg/g 3. Participants need to be in one of the following categories at the time of randomization: - Group I: eGFR 15 to less than 30 mL/min/1.73 m2 , or - Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR > 30 mg/g, or - Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR > 300 mg/g Participants must be a United States Veteran, currently receiving care at a VA hospital with a local study team. Exclusion Criteria: 1. Type 1 diabetes 2. History of non-diabetic kidney disease 3. Severe comorbid conditions expected to reduce life expectancy to less than 1 year, as determined by LSI 4. Active substance abuse, homelessness, or other condition that is likely to result in participant non,ompliance as determined by the LSI 5. Previous organ or bone marrow transplant 6. Pregnancy, breast feeding or female of child-bearing potential unwilling to use a reliable form of contraception 7. A recent (within 3 months) cerebral hemorrhage 8. Current use of oral pentoxifylline 9. Hypersensitivity to pentoxifylline or any of the components of the formulation 10. Current use of systemic ketorolac, oral or IV (contraindicated with pentoxifylline) 11. Current use of riociguat (contraindicated with pentoxifylline) 12. Current use of dialysis 13. Unable to provide informed consent 14. or any condition that in the opinion of the LSI would make the potential participant non-compliant

Study Design


Intervention

Drug:
Pentoxifylline
The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
Placebo
placebo

Locations

Country Name City State
United States New Mexico VA Health Care System, Albuquerque, NM Albuquerque New Mexico
United States VA Ann Arbor Healthcare System, Ann Arbor, MI Ann Arbor Michigan
United States Rocky Mountain Regional VA Medical Center, Aurora, CO Aurora Colorado
United States Bay Pines VA Healthcare System, Pay Pines, FL Bay Pines Florida
United States Cincinnati VA Medical Center, Cincinnati, OH Cincinnati Ohio
United States Harry S. Truman Memorial, Columbia, MO Columbia Missouri
United States Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC Columbia South Carolina
United States VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX Dallas Texas
United States Dayton VA Medical Center, Dayton, OH Dayton Ohio
United States Atlanta VA Medical and Rehab Center, Decatur, GA Decatur Georgia
United States Durham VA Medical Center, Durham, NC Durham North Carolina
United States North Florida/South Georgia Veterans Health System, Gainesville, FL Gainesville Florida
United States Edward Hines Jr. VA Hospital, Hines, IL Hines Illinois
United States Michael E. DeBakey VA Medical Center, Houston, TX Houston Texas
United States Iowa City VA Health Care System, Iowa City, IA Iowa City Iowa
United States Kansas City VA Medical Center, Kansas City, MO Kansas City Missouri
United States Lexington VA Medical Center, Lexington, KY Lexington Kentucky
United States Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR Little Rock Arkansas
United States VA Loma Linda Healthcare System, Loma Linda, CA Loma Linda California
United States VA Long Beach Healthcare System, Long Beach, CA Long Beach California
United States Memphis VA Medical Center, Memphis, TN Memphis Tennessee
United States Clement J. Zablocki VA Medical Center, Milwaukee, WI Milwaukee Wisconsin
United States Minneapolis VA Health Care System, Minneapolis, MN Minneapolis Minnesota
United States Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE Omaha Nebraska
United States VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California
United States Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA Philadelphia Pennsylvania
United States Phoenix VA Health Care System, Phoenix, AZ Phoenix Arizona
United States VA Portland Health Care System, Portland, OR Portland Oregon
United States Hunter Holmes McGuire VA Medical Center, Richmond, VA Richmond Virginia
United States St. Louis VA Medical Center John Cochran Division, St. Louis, MO Saint Louis Missouri
United States Salem VA Medical Center, Salem, VA Salem Virginia
United States VA Salt Lake City Health Care System, Salt Lake City, UT Salt Lake City Utah
United States South Texas Health Care System, San Antonio, TX San Antonio Texas
United States VA Puget Sound Health Care System Seattle Division, Seattle, WA Seattle Washington
United States James A. Haley Veterans' Hospital, Tampa, FL Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to ESRD or death ESRD will be defined as need for chronic dialysis or renal transplantation. 5 to 9 years
Secondary Quality of life (KDQoL-SF) Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF) 5 to 9 years
Secondary Time until doubling of serum creatinine Time until doubling of serum creatinine 5 to 9 years
Secondary Incidence of congestive heart failure hospitalization (CHF) The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years. 5 to 9 years
Secondary Incidence of a three-point MACE The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years. 5 to 9 years
Secondary Incidence of a peripheral vascular disease (PVD) The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years. 5 to 9 years
Secondary Percentage of participants with 50% reduction in UACR from baseline Percentage of participants with 50% reduction in UACR from baseline 5 to 9 years
Secondary Rate of change in eGFR per year during the study period Rate of change in eGFR per year during the study period. 5 to 9 years
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians